Oruka Therapeutics, Inc.
NASDAQ: ORKA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Lawrence Otto Klein
- Employees
- 28
- Headquarters
- Menlo Park, United States
- IPO year
- 1997
- Market cap
- $2.7B
- Website
- http://www.orukatx.com
Loading ORKA…
Loading profile data…Frequently asked questions about ORKA
What does Oruka Therapeutics, Inc. (ORKA) do?
Oruka Therapeutics, Inc. functions as a biotechnology firm primarily dedicated to creating groundbreaking monoclonal antibody therapies. These treatments are designed to address Psoriasis (PsO) along with various other inflammatory and immunological (I&I) conditions. Its current development portfolio includes ORKA-001 and ORKA-002. The company's...
Where does ORKA trade?
Oruka Therapeutics, Inc. (ORKA) trades on the NASDAQ Global Market.
What sector is ORKA in?
Oruka Therapeutics, Inc. (ORKA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Oruka Therapeutics, Inc.?
Lawrence Otto Klein is the chief executive officer of Oruka Therapeutics, Inc. (ORKA).
Where is Oruka Therapeutics, Inc. headquartered?
Oruka Therapeutics, Inc. is headquartered in United States.
Does ORKA pay a dividend?
Yes — Oruka Therapeutics, Inc. (ORKA) paid a trailing twelve-month dividend of USD 19.36 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did ORKA go public?
Oruka Therapeutics, Inc. (ORKA) completed its initial public offering in 1997.